What is the current market valuation of the Non-Small Cell Lung Cancer market?

The market valuation of the Non-Small Cell Lung Cancer market was 20.9 USD Billion in 2024. Read More

What is the projected market size for the Non-Small Cell Lung Cancer market by 2035?

The projected market size for the Non-Small Cell Lung Cancer market is 32.52 USD Billion by 2035. Read More

What is the expected CAGR for the Non-Small Cell Lung Cancer market during the forecast period 2025 - 2035?

The expected CAGR for the Non-Small Cell Lung Cancer market during the forecast period 2025 - 2035 is 4.1%. Read More

Which type of Non-Small Cell Lung Cancer has the highest market valuation?

Adenocarcinoma has the highest market valuation, projected to range from 8.0 to 12.0 USD Billion. Read More

How does the market for Immunotherapy compare to other treatment types?

Immunotherapy is projected to have a market valuation ranging from 3.0 to 5.0 USD Billion, which is lower than Chemotherapy and Targeted Therapy. Read More

What distribution channel is expected to generate the highest revenue in the Non-Small Cell Lung Cancer market?

Hospital Pharmacies are expected to generate the highest revenue, with a projected valuation of 8.0 to 12.0 USD Billion. Read More

Which end user segment is anticipated to dominate the Non-Small Cell Lung Cancer market?

Hospitals are anticipated to dominate the market, with a projected valuation of 8.0 to 12.0 USD Billion. Read More

Who are the key players in the Non-Small Cell Lung Cancer market?

Key players include Roche, Merck & Co, Bristol-Myers Squibb, AstraZeneca, Novartis, Pfizer, Eli Lilly and Company, Amgen, and GSK. Read More

What is the market outlook for the Non-Small Cell Lung Cancer market in the coming years?

The market outlook appears positive, with a projected growth to 32.52 USD Billion by 2035, driven by advancements in treatment and increasing prevalence. Read More

Non Small Cell Lung Cancer Market

Q: What are the key treatment types in the Non-Small Cell Lung Cancer market?

Key treatment types include Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, and Surgery. Read More

ID: MRFR/HC/40522-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Non-Small Cell Lung Cancer Market Research Report: Size, Share, Trend Analysis By Types of Non-Small Cell Lung Cancer (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Other Types), By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Surgery), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies), By End Users (Hospitals, Cancer Treatment Centers, Research Institutions, Home Care Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Non Small Cell Lung Cancer Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.1%

2024 Market Size$ 20.9 Billion

2025 Market Size$ 21.76 Billion

2035 Market Size$ 32.52 Billion

Key Players

Roche

Merck & Co

Bristol-Myers Squibb

AstraZeneca

Novartis

Pfizer

Trends

Rise of Targeted Therapies
Growth of Immunotherapy
Increased Focus on Early Detection

Opportunities

Rising Incidence Rates
Advancements in Precision Medicine
Emergence of Combination Therapies

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Non-Small Cell Lung Cancer (USD Billion)
  1. 4.1.1 Adenocarcinoma
  2. 4.1.2 Squamous Cell Carcinoma
  3. 4.1.3 Large Cell Carcinoma
  4. 4.1.4 Other Types
2. 4.2 Healthcare, BY Treatment Type (USD Billion)
  1. 4.2.1 Chemotherapy
  2. 4.2.2 Radiation Therapy
  3. 4.2.3 Targeted Therapy
  4. 4.2.4 Immunotherapy
  5. 4.2.5 Surgery
3. 4.3 Healthcare, BY Distribution Channel (USD Billion)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Online Pharmacies
  4. 4.3.4 Specialty Pharmacies
4. 4.4 Healthcare, BY End User (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Cancer Treatment Centers
  3. 4.4.3 Research Institutions
  4. 4.4.4 Home Care Settings
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GSK (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 CANADA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
10. 6.10 CANADA MARKET ANALYSIS BY END USER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
15. 6.15 GERMANY MARKET ANALYSIS BY END USER
16. 6.16 UK MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
17. 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE
18. 6.18 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
19. 6.19 UK MARKET ANALYSIS BY END USER
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
23. 6.23 FRANCE MARKET ANALYSIS BY END USER
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
28. 6.28 ITALY MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
31. 6.31 ITALY MARKET ANALYSIS BY END USER
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
35. 6.35 SPAIN MARKET ANALYSIS BY END USER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE
43. 6.43 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
44. 6.44 CHINA MARKET ANALYSIS BY END USER
45. 6.45 INDIA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE
47. 6.47 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
48. 6.48 INDIA MARKET ANALYSIS BY END USER
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
52. 6.52 JAPAN MARKET ANALYSIS BY END USER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
64. 6.64 THAILAND MARKET ANALYSIS BY END USER
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
81. 6.81 MEXICO MARKET ANALYSIS BY END USER
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF NON-SMALL CELL LUNG CANCER
100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE OF NON-SMALL CELL LUNG CANCER, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE OF NON-SMALL CELL LUNG CANCER, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF NON-SMALL CELL LUNG CANCER, 2025-2035 (USD Billion)
  2. 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Non Small Cell Lung Cancer Market Segmentation

Non Small Cell Lung Cancer Market By Type of Non-Small Cell Lung Cancer (USD Billion, 2025-2035)

Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Other Types

Non Small Cell Lung Cancer Market By Treatment Type (USD Billion, 2025-2035)

Chemotherapy
Radiation Therapy
Targeted Therapy
Immunotherapy
Surgery

Non Small Cell Lung Cancer Market By Distribution Channel (USD Billion, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies

Non Small Cell Lung Cancer Market By End User (USD Billion, 2025-2035)

Hospitals
Cancer Treatment Centers
Research Institutions
Home Care Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”